Publication: Dirençli Glokom Olgularında Diod Laser Siklofotokoagülasyon Tedavisi Sonuçları
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Abstract
AMAÇ: Tıbbi ve cerrahi tedavi yöntemlerinin göz içi basıncı kontrolünü sağlayamadığı dirençli glokom olgularında transskleral diod lazer siklofotokoagülasyon tedavisinin etkinliğinin değerlendirilmesi GEREÇ VE YÖNTEM: 2003-2014 tarihleri arasında Ondokuzmayıs Üniversitesi Tıp Fakültesi Göz Hastalıkları Anabilim Dalı Glokom Birimi'nde takipte olan veya yeni başvuran medikal ve cerrahi tedaviye dirençli ileri glokomu olup transskleral diod lazer siklofotokoagülasyon tedavisi yapılan 78 hastanın 79 gözü çalışmaya alındı. Çalışmaya alınan tüm hastaların görme keskinlikleri, biyomikroskobik ön segment (konjonktival hiperemi, korneal ödem, ön kamarada inflamasyon varlığı ve şiddeti), arka segment muayene bulguları, kullanılan antiglokomatöz ilaçlar kaydedildi. Tedavi öncesi ve sonrası 1. gün, 1. hafta, 1. ay, 3. ay, 6. ay ve son kontroldeki göz içi basınçları (GİB) kaydedildi. BULGULAR: Hastaların 43'ü (%55,1) kadın, 35'i (%44,9) erkek olup yaş ortalamaları 63,8±17,5 (14-103) idi. Ortalama takip süresi 14,7±14,6 ay (minimum 1 hafta, maksimum 72 ay) idi. 79 gözün 45'i (%56,9) neovasküler glokom (NVG), 15'i (%18,9) sekonder glokom, 9'u (%11,9) primer açık açılı glokom (PAAG), 7'si (%8,8) pseudoeksfoliyatif glokom, 3'ü (%3,7) dar açılı glokomdu. Preoperatif ortalama GİB 42,5±9,5 mmHg'dan 6. ayda 26,2±12,1 mmHg'ye düştü; 16,3 mmHg (%38,4) GİB düşüşü sağlandı. Bu düşüş istatistiksel olarak anlamlıydı (p<0,001). Son kontrolde 39 (%49,4) gözde GİB 22 mmHg ve altında idi. Hastalara en fazla iki seans tedavi uygulandı. Kullanılan antiglokomatöz ilaç etken madde sayısı lazer öncesi 3,6±1.1 iken lazer sonrası 2,2±1,4'e düştü (p<0,001). Preoperatif ağrısı olan 78 gözün 76'sında (%97,4) ağrı semptomu kayboldu, preop hiperemisi olan 77 gözün 72'sinde (%93,5) hiperemi kayboldu, preop korneal ödemi olan 65 gözün 55'inde (%84,6) korneal ödem kayboldu. 63 gözde (%79,7) lazer sonrası komplikasyon olmadı. 3 gözde (%3,8) epitelyum defekti, 1 gözde (%1,2) korneal incelme, 1 gözde (%1,2) nörotrofik keratit, 11 gözde üveit (%13,9), 4 gözde (%5) hifema gelişti. Gözlerin %77,2'sinde görme keskinliği değişmedi; %6,3'ünde görme keskinliğinde artış olurken, %16,5'inde görme keskinliğinde azalma oldu. SONUÇ: Transskleral diod lazer siklofotokoagülasyon tedavisi, tıbbi ve cerrahi tedavi yöntemleri ile GİB kontrol altına alınamayan dirençli glokom olgularında etkili ve güvenilir bir tedavi seçeneğidir.
PURPOSE: To evaluate the efficiency of transscleral diode laser cyclophotocoagulation treatment in resistant glaucoma cases whose intraocular pressure cannot be controlled by medical and surgical treatment methods. MATERIAL AND METHOD: Seventy nine eyes of 78 patients treated with transscleral diode laser cyclophotocoagulation who had medical and surgical treatment resistant advanced glaucoma and who were being followed by Ondokuzmayıs University, Faculty of our Medicine, Department of Ophthalmology, Glaucoma Unit or who had recently applied to the Unit, were included in the study. In this study the patients' visual acuity, their biomicroscopic anterior segment (conjunctival hyperemia, corneal edema, presence and severity of inflammation on the anterior chamber) and posterior segment examination results and the antiglaucoma drugs used were recorded. Intraocular pressure (IOP) on the first day before and after treatment, first week, first month, third month, sixth month and the last control were recorded. FINDINGS: Forty-three (55,1%) of the patients were female while 35 (44,9%) were male. The mean age of the patients was 63,8±17,5 (14-103). The mean follow-up period of the patients was 14,7±14,6 months (minimum 1 week, maximum 72 months). Of the 79 eyes, 45 (%56,9) were neovascular glaucoma, 15 (18,9%) were secondary glaucoma, 9 (%11,9) were primary open-angle glaucoma, 7 (8,8%) were pseudoexfoliative glaucoma and 3 (3,7%) were narrow-angle glaucoma. Preoperative average IOP fell from 42,5±9,5 mmHg to 26,2±12,1 mmHg in the sixth month; there was a decrease of 16,3 mmHg (38,4%). This decrease was statistically significant (p<0,001). In the last control, IOP was 22 mmHg and lower in 39 eyes (49,5%). The patients had two sessions of treatment at most. The number of antiglaucoma drugs active substance decreased from 3,6±1.1 to postoperative 2,2±1,4 (p<0,001). Of the 78 eyes that had preoperative pain, pain symptom disappeared in 76 (97,4%); of the 77 eyes that had preoperative hyperemia, hyperemia disappeared in 72 (93,5%) and of the 65 eyes that had preoperative corneal edema, corneal edema disappeared in 55 (84,6%). No postlaser complications were seen in 63 eyes (79,7%). Postlaser complications were seen that epithelium defect in 3 eyes (3,8%), corneal thinning in 1 eye (1,2%), neurothropic keratitis in 1 eye (1,2%), uveitis in 11 eyes (%13,9) and hyphema in 4 eyes (5%). Visual acuity did not change in 77,2 % of the eyes while there was an increase in 6,3 % and a decrease in 16,5%. CONCLUSION: Transscleral diode laser cyclophotocoagulation treatment is an effective and safe treatment option in resistant glaucoma cases whose intraocular pressure cannot be controlled by medical and surgical treatment methods.
PURPOSE: To evaluate the efficiency of transscleral diode laser cyclophotocoagulation treatment in resistant glaucoma cases whose intraocular pressure cannot be controlled by medical and surgical treatment methods. MATERIAL AND METHOD: Seventy nine eyes of 78 patients treated with transscleral diode laser cyclophotocoagulation who had medical and surgical treatment resistant advanced glaucoma and who were being followed by Ondokuzmayıs University, Faculty of our Medicine, Department of Ophthalmology, Glaucoma Unit or who had recently applied to the Unit, were included in the study. In this study the patients' visual acuity, their biomicroscopic anterior segment (conjunctival hyperemia, corneal edema, presence and severity of inflammation on the anterior chamber) and posterior segment examination results and the antiglaucoma drugs used were recorded. Intraocular pressure (IOP) on the first day before and after treatment, first week, first month, third month, sixth month and the last control were recorded. FINDINGS: Forty-three (55,1%) of the patients were female while 35 (44,9%) were male. The mean age of the patients was 63,8±17,5 (14-103). The mean follow-up period of the patients was 14,7±14,6 months (minimum 1 week, maximum 72 months). Of the 79 eyes, 45 (%56,9) were neovascular glaucoma, 15 (18,9%) were secondary glaucoma, 9 (%11,9) were primary open-angle glaucoma, 7 (8,8%) were pseudoexfoliative glaucoma and 3 (3,7%) were narrow-angle glaucoma. Preoperative average IOP fell from 42,5±9,5 mmHg to 26,2±12,1 mmHg in the sixth month; there was a decrease of 16,3 mmHg (38,4%). This decrease was statistically significant (p<0,001). In the last control, IOP was 22 mmHg and lower in 39 eyes (49,5%). The patients had two sessions of treatment at most. The number of antiglaucoma drugs active substance decreased from 3,6±1.1 to postoperative 2,2±1,4 (p<0,001). Of the 78 eyes that had preoperative pain, pain symptom disappeared in 76 (97,4%); of the 77 eyes that had preoperative hyperemia, hyperemia disappeared in 72 (93,5%) and of the 65 eyes that had preoperative corneal edema, corneal edema disappeared in 55 (84,6%). No postlaser complications were seen in 63 eyes (79,7%). Postlaser complications were seen that epithelium defect in 3 eyes (3,8%), corneal thinning in 1 eye (1,2%), neurothropic keratitis in 1 eye (1,2%), uveitis in 11 eyes (%13,9) and hyphema in 4 eyes (5%). Visual acuity did not change in 77,2 % of the eyes while there was an increase in 6,3 % and a decrease in 16,5%. CONCLUSION: Transscleral diode laser cyclophotocoagulation treatment is an effective and safe treatment option in resistant glaucoma cases whose intraocular pressure cannot be controlled by medical and surgical treatment methods.
Description
Tez (tıpta uzmanlık) -- Ondokuz Mayıs Üniversitesi, 2014
Libra Kayıt No: 110102
Libra Kayıt No: 110102
Citation
WoS Q
Scopus Q
Source
Volume
Issue
Start Page
End Page
81
